Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Q1 2025 saw around $152M flow into psychedelics companies, with Lykos Therapeutics’ $50M Series B round representing one of the first major private financings in quite some time. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q1 roundup.
In a candid conversation with Psychedelic Alpha’s Josh Hardman, former U.S. Senator Kyrsten Sinema shares her case for ibogaine, sidesteps what she describes as ‘drama’, and lays out a strategy for funding research into the atypical psychedelic. Framing FDA approval as the north star, Sinema positions ibogaine as a transformative treatment option for conditions ranging from PTSD through to traumatic brain injury and Parkinson’s.
As the first cut of data from Oregon’s psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment of our new Oregon Psilocybin Services Tracker, which will produce analysis of each cut of data as it is released. ∎
Psychedelic Alpha’s Charles Bliss speaks with Chris Timmermann, Research Fellow in Neuroscience, Meditation and Psychedelics at University College London, about why understanding and integrating psychedelic experiences may be just as vital for personal growth as for treating mental illness.
We cover Beckley Psytech and atai Life Sciences’ conference call this morning, where company executives provided further details on the Phase 2b readout of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression and took aim at their closest competitor’s model.
This morning, Beckley Psytech shares topline data from its Phase 2b study of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). The study, the largest of the drug to date, printed positive results, with a significant and rapid antidepressant effect and favourable safety profile. Here, we take a closer look at the results and share our quick-take analysis with reference to GH Research’s similar Phase 2b study.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
This is an archived version of our Psychedelic News Feed, from December 11 2023 – January 7 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
